Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
Sensei Biotherapeutics (NASDAQ: SNSE) will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2026 at 12:45 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
The live webcast of the presentation may be accessed via the Events and Presentations section of the Sensei website at investors.senseibio.com. A replay of the webcast will be available for approximately 90 days following the event.
About Sensei Biotherapeutics
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. Following the acquisition of Faeth Therapeutics, Sensei's lead program is PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. Sensei is also completing a Phase 1/2 trial of solnerstotug, its V-domain Ig suppressor of T cell activation (VISTA) inhibitor, in patients with advanced solid tumors. Sensei intends to use its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, please visit www.senseibio.com and follow the company on X @SenseiBio and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260409316060/en/
Investor Contact:
Stephanie Ascher, Precision AQ
Stephanie.ascher@precisionaq.com
Media Contact:
Patrick Schmidt, Consort Partners
senseibio@consortpartners.com
Source: Sensei Biotherapeutics, Inc.